COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 14th April 2020. As a result, our offices will now be closed till 14th April 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details. editor@innovativepublication.com, rakesh.its@gmail.com, Mob. 8826373757, 8826859373, 9910947804

Article view: 388

Article download: 153

Indian Journal of Clinical and Experimental Ophthalmology


Efficacy and safety of subconjuctival bevacizumab injection in the management of pterygium


Full Text PDF Share on Facebook Share on Twitter


Author Details : Meenakshi Pathania, VS Gurunadh, MA Khan

Volume : 4, Issue : 2, Year : 2018

Article Page : 209-212


Suggest article by email


Abstract

Purpose: To assess the efficacy and safety of sub-conjunctival bevacizumab in the management of grade II and III pterygium.
Materials and Methods: Cases of pterygium with no other ocular abnormality and with no systemic disorders were subjected to anterior segment photography and graded. Ten cases of grade III pterygium and eleven cases of grade II pterygium were administered subconjunctival intralesional injection of 2.5mg/0.1ml of bevacizumab. Anterior segment photographs were taken on day 7, day 28 and day 90 along with complete ocular examination and general physical examination. The pterygium vascularity, size and thickness were assessed keeping note of any adverse effects ophthalmic or otherwise. An evaluation of the symptoms before injection and at day 90 was also done.
Results: There was statistically significant improvement in the grade, color, intensity, size of pterygium, and symptoms of patients. There was a decrease in symptoms of redness, itching, watering, and irritation.
Of the 10 cases with Grade III on enrollment, 08 (80%) had shown a decrease in vascularity with half of them graded as II and the remaining half as grade I.
Of the 11 cases of Grade II
pterygium at baseline, 05 (45%) cases changed to grade I by day 90.
Conclusion: This study revealed that the sub-conjunctival injection of bevacizumab was found to be useful in reduction of symptoms of patients with grade III & II pterygium with no local or systemic adverse effects.

Keywords: Bevacizumab, Pterygium, Subconjuctival, Treatment.

Doi : 10.18231/2395-1451.2018.0046

How to cite : Pathania M, Gurunadh V, Khan M, Efficacy and safety of subconjuctival bevacizumab injection in the management of pterygium. Indian J Clin Exp Ophthalmol 2018;4(2):209-212

Copyright © 2018 by author(s) and Indian J Clin Exp Ophthalmol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (creativecommons.org)